10.1136/POSTGRADMEDJ-2020-138234 doi: 10.1016/j.jaad.2021.03.092, 15. Epub 2022 Feb 9. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review. PRISMA flowchart. Background: National Library of Medicine Accessibility See this image and copyright information in PMC. Epub 2021 Jul 21. Please enable it to take advantage of the complete set of features! HHS Vulnerability Disclosure, Help Rashes show as hives, bumps or . Federal government websites often end in .gov or .mil. Pityriasis Rosea Associated With COVID-19 Vaccination: A Common Rash Following Administration of a Novel Vaccine. A 52-year-old Thai woman with a one-year history of recurrent glioblastoma was admitted to our hospital for a planned targeted therapy. FOIA [Epub ahead of print]. Please enable it to take advantage of the complete set of features! However, some hypotheses may be advanced: PR/PRLE following anti-Sars-CoV-2 vaccination may be just a coincidence; anti-Sars-CoV-2 vaccines cause a reactivation of HHV-6 and/or HHV-7; vaccines can induce a delayed hypersensitivity response clinically similar to drug-induced PRLE. KL and KP collated resources. and transmitted securely. Pityriasis rosea is a common self-limiting rash that usually starts with a herald patch on the trunk and progresses along the Langer lines to a generalized rash over the trunk and limbs. (2019) 34:185764. No HHV-6 and HHV-7 reactivation is detected. and transmitted securely. 2021 Sep;34(5):e15040. COVID-19 is an infectious disease caused by SARS-CoV-2, which emerged in China in 2019 and rapidly spread worldwide to become a pandemic in March 2020. Among patients who received COVID-19 vaccines, PR-like eruptions have been reported following the first (n = 1) or second dose (n = 2) of BNT162b2 mRNA-based vaccines (3, 4). 2020;33:E13730. Bin Rubaian NF, Almuhaidib SR, Aljarri SA, Alamri AS. The four stages of pityriasis rosea are: Preliminary stage: You feel ill for a day or two. Authors Jordan E Buckley 1 , Laura N Landis 2 , Ronald P Rapini 1 Affiliations Many Americans become infected with them at an early age. Laboratory investigation results (i.e., complete blood count, blood chemistry, C-reactive protein level, erythrocyte sedimentation rate, serological test for syphilis, plasma polymerase chain reaction (PCR) for human herpesvirus (HHV)-6 and HHV-7, and reverse transcription-PCR for COVID-19) were unremarkable. Dermatol Ther. The .gov means its official. Physical examination revealed that lesions were distributed along cleavage lines, similar to PR, without herald patch or prominent scales (Figure 1C). doi: 10.1002/jmv.26549, 9. Factors affecting the severity of central centrifugal cicatricial alopecia. Methods: Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. Globally, as of 7:26 pm CEST, 10 October 2022, there have been 618,521,620 confirmed cases of COVID-19, including 6,534,725 deaths, reported to the WHO. Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin. PR 12.7 days (mean) after the vaccination (19 patients after the 1. Ciccarese G, Parodi A, Drago F. SARS-CoV-2 as possible inducer of viral reactivations. 2021 Aug;35(8):e491-e493. 2022 Nov-Dec;67(6):802-804. doi: 10.4103/ijd.ijd_562_22. Bookshelf A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea-like eruptions after vaccination, out of which 36 (55.38%) were female. -. Clin Dermatol. 8:752443. doi: 10.3389/fmed.2021.752443. N Engl J Med 2020; 383: 2603-2615. Conflicts of Interests: The authors declare there are no competing interests. Dermatol Reports. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations. Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. This is called the herald patch. Herald patch of pityriasis rosea. 2021 Dec;108(6):317-318. doi: 10.12788/cutis.0411. Bethesda, MD 20894, Web Policies J Am Acad Dermatol. Variable dermatological manifestations including acral erythema, urticaria, vasculitis, vesicular or pustular eruptions, maculopapular rash have all been reported during the course of COVID19. Moreover, COVID-19 may solely induce human herpesvirus reactivation through the immunomodulatory ability of SARS-CoV-2 to reactivate latent viruses (8, 9). It may or may not be itchy and usually lasts six to eight weeks before resolving on its own. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature JAAD Int. Unauthorized use of these marks is strictly prohibited. Veraldi S, Boneschi V, Cusini M, Maronese CA. JAAD Int. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. A number of vaccines have been produced to combat the current COVID-19 pandemic, and a variety of side effects have been recorded following the vaccination. Pregnant women are in a high-risk group for serious complications from pityriasis rosea. Federal government websites often end in .gov or .mil. doi: 10.1111/bjd.20143. Marcantonio-Santa Cruz OY, Vidal-Navarro Y, Pesqu D, et al.. Pityriasis rosea developing after COVID-19 vaccination. Unable to load your collection due to an error, Unable to load your delegates due to an error. Federal government websites often end in .gov or .mil. Cite this: Skin Reactions After COVID-19 Vaccination . Complete remission was observed within 14-30 days. A history of viral infection preceding the disease was reported COVID19 MapJohns Hopkins Coronavirus Resource Center. and transmitted securely. Herald patch in the right hypochondrium followed by typical oval-shaped secondary plaques, Pityriasis rosea lesions on the upper extremities, MeSH To the best of our knowledge, only one case of ChAdOx1 nCoV-19 vaccine-induced PR-like eruption has been reported (2). Thirty-one studies were included for data extraction after screening following the eligibility criteria. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. 2022 May;35(5):e15391. Veraldi S, Boneschi V, Cusini M, Maronese CA. If you develop pityriasis rosea, you may experience the following in this order: Feel ill for 1 or 2 days Develop a large patch on your skin Get many smaller patches or bumps on your skin See your skin clear All patients were treated with cetirizine. Figure 3. -, Carballido Vzquez AM, Morgado B. Pityriasis rosea-like eruption after PfizerBioNTech COVID-19 vaccination. 2023 The Authors. The site is secure. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. PRISMA flowchart. The https:// ensures that you are connecting to the Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine. doi: 10.1111/jdv.17498. Pityriasis rosea is generally benign and most of the time will not come back after a patient has recovered, but in a small number of cases the condition recurs which may be a sign, there is another underlying condition causing the rash.. Please enable it to take advantage of the complete set of features! and transmitted securely. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. PRISMA, preferred reporting items for systematic reviews and metaanalysis. Due to the rising incidence of coronavirus disease 2019 (COVID-19) worldwide, mass vaccination has been the cornerstone in preventing viral spread and decreasing morbidity and mortality. (2021) 85:4655. PMC Complete remission was observed within 14-30 days. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. Cases of EM was observed after mRNA-based COVID-19 vaccines, and after CoronaVac vaccination wich is is an inactivated SARS-CoV-2 virus [13, 14]. sharing sensitive information, make sure youre on a federal Cazzato G, Ambrogio F, Foti C, Capuzzolo M, Trilli I, Casatta N, Lupo C, Carrieri M, Daini D, Colagrande A, Maiorano E, Ingravallo G. Diagnostics (Basel). J Eur Acad Dermatol Venereol. However, there are limited data on the negative effects of immunological reactivation following vaccination. +39.3465909404. official website and that any information you provide is encrypted Although histopathologic characteristics of PR are also observed in PR-like lesions, the presence of dyskeratotic keratinocytes, interface dermatitis, and eosinophilic infiltration in the dermis may be more prominent in PR-like eruptions (11). Previously, PR has been reported in temporal association with various viral inoculations. The https:// ensures that you are connecting to the Although the exact pathophysiologic mechanisms of PR after vaccination remain unclear, immune responses to COVID-19 vaccines and disruption of T-cell mediated control of latent infections were implicated (12, 1518). government site. (2021) 60:11501. However, some hypotheses may be advanced: i) PR/PRLE following anti- Sars-CoV-2 vaccination may be just a coincidence, for instance in those patients in whom PR/PRLE appeared only one day after vaccination;4,12 ii) anti-Sars-CoV-2 vaccines cause a reactivation of HHV-6 and/or HHV-7, which is similar to the reported association with herpes zoster;1,9 iii) vaccines can induce a delayed hypersensitivity response clinically similar to druginduced PRLE.10. In addition to COVID-19 vaccination, she was currently taking medications (i.e., levetiracetam and thyroxin) for glioblastoma, and the two drugs had been prescribed for approximately nine months. official website and that any information you provide is encrypted The rash typically lasts 6-9 weeks, rarely extending longer than 12 weeks. Bathe or shower in lukewarm water. Received 2022 Mar 26; Accepted 2022 Apr 25. As a library, NLM provides access to scientific literature. Results were superimposable: parakeratosis, mild spongiosis, acanthosis and exocytosis were seen in the epidermis. Clipboard, Search History, and several other advanced features are temporarily unavailable. doi: 10.1002/iid3.804. 2023 Mar 3;14(2):207-212. doi: 10.4103/idoj.idoj_449_22. Cutis. . There are four main types of vaccines and over 240 candidate vaccines in development. See this image and copyright information in PMC. Unable to load your collection due to an error, Unable to load your delegates due to an error. Keywords: adverse effect, coronavirus, cutaneous eruptions, immunization, pityriasis rosea, SARS-CoV-2, vaccine, case report, Citation: Leerunyakul K, Pakornphadungsit K and Suchonwanit P (2021) Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination. It can take 1 to 3 months to go away. In an American study, the average latency time was 13 days.7 In the previous cited Turkish-Egyptian study, the average latency time was 12.7 days.17 In 22 cases the eruption appeared 1-21 days after the second dose (average: 8.8 days); in 2 cases the eruption occurred both after the first and the second dose. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). eCollection 2023 Mar-Apr. Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. It is possible that a relationship anti- Sars-CoV-2 vaccinationPR/PRLE exists; however, it is very rare, in consideration of millions of vaccinated subjects and the low number of reported cases with PR/PRLE. In 4 patients PR appeared after the first vaccination; in one patient after the second one. eCollection 2023 Mar 7. Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination. 2005;124(6):12341240. N Engl J Med 2020; 383:260315.